Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics-Reference-Cited by-同舟云学术

Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics

Published:2023-05 Issue:16 Volume:19 Page:1113-1124
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

DeClue Richard W¹,Szamreta Elizabeth A²,Gautam Santosh¹^ORCID,Fisher Maxine D¹,Monberg Matthew J²

Affiliation:

1. ConcertAI, Cambridge, MA 02138, USA

2. Merck & Co., Inc., Rahway, NJ 07065, USA

Abstract

Aim: Real-world data on treatment patterns and outcomes of advanced ovarian cancer (OC) patients since bevacizumab approval in first-line (1L) OC treatment were assessed. Materials & methods: In this descriptive retrospective study using the ConcertAI Oncology Dataset, patient characteristics, treatment patterns and real-world progression-free survival (rwPFS) from start of 1L were evaluated among patients diagnosed with advanced OC between 2011–2020. Treatment data from structured sources were confirmed and/or supplemented by human review of unstructured data. Results: Median rwPFS for bevacizumab and non bevacizumab cohorts was 17.3 months (95% CI: 14.9, 20.4) and 15.7 months (95% CI: 12.3, 29.1), respectively. Patients with ≥10 doses during 1L had higher median rwPFS compared with patients receiving 3–9 doses. Conclusion: This real-world study suggests benefits of bevacizumab treatment in advanced OC were primarily experienced by patients who received ≥10 doses in 1L.

Funder

Merck

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0955

Reference25 articles.

1. Cancer statistics, 2023

2. Surveillance Epidemiology and End Results. SEER cancer stat facts: ovarian cancer. (7 February 2023). https://seer.cancer.gov/statfacts/html/ovary.html

3. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer V.4.2022. © National Comprehensive Cancer Network, Inc (2022). www.nccn.org/guidelines/permission-to-cite-or-use-nccn-content Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer V.4.2022. ©National Comprehensive Cancer Network, Inc. 2022. All right reserved. Accessed September 8, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

5. Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer